Zalán Péterfi
CEO
VRG Therapeutics
VRG Therapeutics specializes in the design and optimization of miniprotein-based therapeutics using an AI-driven drug discovery platform that combines scaffold selection with wet lab screening. This approach enables rapid hit validation within six months and significantly reduces preclinical development costs for treatments targeting autoimmune diseases, chronic inflammatory diseases, and oncology.
- Artificial Intelligence
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$5.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional drug discovery processes for miniprotein-based therapeutics are often slow and costly, hindering the rapid development of treatments for autoimmune diseases, chronic inflammatory diseases, and oncology. Existing methods may lack the speed and efficiency needed to identify and validate promising drug candidates within a reasonable timeframe and budget.
Solution
VRG Therapeutics addresses these challenges with an AI-driven drug discovery platform that accelerates the design and optimization of miniprotein-based therapeutics. The platform combines AI-powered scaffold selection with state-of-the-art wet lab screening and in vivo characterization, enabling rapid hit validation within six months. This integrated approach significantly reduces preclinical development costs while ensuring exceptional selectivity towards any drug target. VRG Therapeutics' platform facilitates the creation of novel therapeutic candidates with unprecedented selectivity and affinity, addressing major unmet clinical needs in autoimmune diseases, inflammation, and oncology.
Target Audience
VRG Therapeutics primarily targets pharmaceutical companies and research institutions seeking to accelerate their drug discovery process and develop novel therapeutics for autoimmune diseases, chronic inflammatory diseases, and oncology.
Features
- AI-powered de novo scaffold selection for any target
- State-of-the-art wet lab screening for exceptional selectivity
- Integrated in vivo facility for animal characterization
- Miniprotein-based drug discovery platform leveraging AI-driven scaffold selection
- Capability to design and optimize miniproteins with high stability, solubility, and low immunogenicity
- Identification of synergistic drug combinations for enhanced therapeutic effects, such as VRG-145 for migraine prophylaxis
- Focus on precision targeting of well-validated but difficult targets